Multidrug-resistant bacteria in hospitalized patients with cystic fibrosis: a retrospective cross-sectional study

Yıl 2025, Cilt: 7 Sayı: 5, 630 - 634, 15.09.2025

Serkan Atıcı , Emine Atağ , Bülent Karadağ , Ahmet Soysal

https://doi.org/10.38053/acmj.1741140

Öz

Aims: The emergence of multidrug-resistant (MDR) bacterial pathogens has become a critical clinical challenge in cystic fibrosis (CF) patients. This study aimed to characterize MDR bacterial isolates in hospitalized CF patients experiencing pulmonary exacerbations.
Methods: We defined MDR as resistance to three or more antimicrobial classes. The study included 45 acute exacerbation episodes with confirmed MDR bacterial growth among 32 CF pediatric patients hospitalized at Marmara University Pendik Training and Research Hospital.
Results: Among 32 CF patients (mean age: 114.7±62.1 months; 68.8% female), we analyzed 45 exacerbation episodes. The most common clinical manifestations were increased sputum production (73.3%), cough (60%), and fever (31%). Pseudomonas aeruginosa colonization was previously documented in 55.6% of cases. Respiratory cultures revealed MDR bacteria in all patients, with P. aeruginosa (53.4%), Staphylococcus aureus (17.8%), and Acinetobacter baumannii (4.4%) being the predominant isolates. Combination antibiotic therapy was required in 82% of cases (37/45), while only 18% (8/45) received monotherapy. The mean hospitalization duration was 17.3±8.4 days, with an overall mortality rate of 6.2% (n=2).
Conclusion: MDR infections in CF patients demand a multifaceted approach. Rotating antibiotic regimens and avoiding carbapenem overuse may reduce resistance. Tailored antibiotic regimens and antimicrobial stewardship programme, robust infection controls such as enhanced screening for MDR colonization and isolation protocols are needed to curb transmission, and sustained research into emerging pathogens. Our data reinforce the urgent need for CF-specific antimicrobial protocols in Turkiye and similar countries.

Anahtar Kelimeler

Cystic fibrosis , multidrug-resistant , hospitalized patients

Hastanede yatan kistik fibrozis hastalarında çoklu ilaca dirençli bakteriler: retrospektif kesitsel bir çalışma

Öz

Amaç: Çoklu ilaca dirençli (ÇİD) bakteriyel patojenlerin ortaya çıkışı, kistik fibroz (KF) hastalarında kritik bir klinik sorun haline gelmiştir. Bu çalışma, hastanede yatan ve alevlenmeler yaşayan KF hastalarında ÇİD bakteri izolatlarını karakterize etmeyi amaçlamıştır.
Yöntemler: ÇİD'yi, üç veya daha fazla antimikrobiyal sınıfa direnç olarak tanımladık. Çalışmaya, Marmara Üniversitesi Pedik Eğitim ve Araştırma Hastanesi'nde yatan 32 KF hastası arasında doğrulanmış ÇİD bakteri üremesi olan 45 akut alevlenme atağı dahil edildi.
Sonuçlar: 32 KF hastası (ortalama yaş: 114,7 ± 62,1 ay; %68,8'i kadın) arasında, 45 alevlenme atağı tesbit edildi. En sık görülen klinik bulgular balgamda artış (%73,3), öksürük (%60) ve ateş (%31) idi. Pseudomonas aeruginosa kolonizasyonu vakaların %55,6'sında mevcuttu. Tüm hastaların solunum yolu kültürlerinde ÇİD bakteri üremesi vardı. P. aeruginosa (%53,4), Staphylococcus aureus (%17,8) ve Acinetobacter baumannii (%4,4) baskın izolatlardı. Vakaların %82'sinde (37/45) kombine antibiyotik tedavisi gerekirken, sadece %18'ine (8/45) monoterapi uygulandı. Ortalama hastanede kalış süresi 17,3±8,4 gündü ve genel mortalite oranı %6,2'ydi (n=2).
Sonuçlar: Kistik fibrozis hastalarında ÇİD enfeksiyonların takibi ve tedavisi multidisipliner yaklaşım gerektirir. Antibiyotik rejimlerinin dönüşümlü olarak uygulanması ve karbapenem aşırı kullanımından kaçınılması direnci azaltabilir. Bulaşmayı azaltmak için hasta özelinde antibiyotik rejimleri ve antimikrobiyal yönetim programları gereklidir. ÇİD kolonizasyonu için gelişmiş tarama ve izolasyon protokolleri gibi güçlü enfeksiyon kontrolleri ve yeni ortaya çıkan patojenler üzerinde sürekli araştırmalara ihtiyaç vardır. Verilerimiz, Türkiye ve benzeri ülkelerde KF'ye özgü antimikrobiyal tedavi protokollerine ihtiyaç olduğunu desteklemektedir.

Anahtar Kelimeler

Kistik fibroz , çoklu ilaç direnci , hastanede yatan hastalar

Kaynakça

• Aydemir Ö, Kiper N. Cystic fibrosis disease in the world and Turkey. J Int Med Sci. 2007;3(14):1-3.
• Conway SP, Brownlee KG, Denton M, Peckham DG. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med. 2003;2(4):321-332. doi:10.1007/BF03256660
• Fainardi V, Neglia C, Muscarà M, et al. Multidrug-resistant bacteria in children and adolescents with cystic fibrosis. Children (Basel). 2022;9(9): 1330. doi:10.3390/children9091330
• World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report: 2021. [accessed: May 10, 2025]https://iris.who.int/handle/10665/341666.
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281. doi:10. 1111/j.1469-0691.2011.03570.x
• Cromwell EA, Ostrenga JS, Todd JV, et al. Cystic fibrosis prevalence in the United States and participation in the cystic fibrosis foundation patient registry in 2020. J Cyst Fibros. 2023;22(3):436-442. doi:10.1016/j.jcf.2023.02.009
• Wood SJ, Kuzel TM, Shafikhani SH. Pseudomonas aeruginosa: infections, animal modeling, and therapeutics. Cells. 2023;12(1):199. doi:10.3390/cells12010199
• Almulhem M, Ward C, Haq I, Gray RD, Brodlie M. Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review. BMJ Open Respir Res. 2024;11(1):e002456. doi:10.1136/bmjresp-2024- 002456
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 25th informational supplement. CLSI document M100-S25. Wayne, PA: CLSI 2015.
• Cystic Fibrosis Foundation. 2023 Patient Registry Annual Data Report [Internet]. Bethesda, MD: Cystic Fibrosis Foundation; 2024 [cited 2025 May 10]. Available from: https://www.cff.org/medical-professionals/patient-registry
• UK Cystic Fibrosis Registry. 2022 Annual Data Report [Internet]. London: UK Cystic Fibrosis Trust; 2023 [cited 2025 May 10]. Available from: https://www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry/ reports-and-data
• European Cystic Fibrosis Society. Patient Registry 2022: Key Findings [Internet]. Copenhagen: ECFS; 2023 [cited 2025 May 10]. Available from: https://www.ecfs.eu/projects/patient-registry
• Rocha GA, Lima DF, Rodrigues ER, et al. Species distribution, sequence types and antimicrobial resistance of Acinetobacter spp. from cystic fibrosis patients. Epidemiol Infect. 2018;146(4):524-530. doi:10.1017/S 0950268817002849
• Moubareck CA, Halat DH. Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics (Basel). 2020;9(3):119. doi:10.3390/antibiotics9030119
• Ranganathan SC, Hall GL, Sly PD, Stick SM, Douglas TA; AREST CF. Early lung disease in infants and preschool children with cystic fibrosis: what have we learned, and what should we do about it? Am J Respir Crit Care Med. 2017;195(12):1567-1575. doi:10.1164/rccm.201606-1107CI
• Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society standards of care: best practice guidelines. J Cyst Fibros. 2014;13(Suppl 1):S23-42. doi:10.1016/j.jcf.2014.03.010
• Waters V, Smyth A. Cystic fibrosis microbiology: advances in antimicrobial therapy. J Cyst Fibros. 2015;14(5):551-560. doi:10.1016/j.jcf.2015.02.005